Cash, cash equivalents and investments as of September 30, 2025, were $66.5 million. The Company believes its cash, cash equivalents and investments are sufficient to fund planned operations into Q1 of 2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO:
- ALXO Earnings this Week: How Will it Perform?
- Alx Oncology’s ALX2004: A Promising Phase 1 Study Targeting EGFR in Solid Tumors
- ALX Oncology’s ASPEN-09 Study: A Promising Update for Cancer Treatment
- ALX presents preclinical data, Phase 1 trial-in-progress for ALX2004
- ALX Oncology Announces Management Changes Amidst Nasdaq Compliance